DNLI
Price
$13.83
Change
-$0.17 (-1.21%)
Updated
Jul 21 closing price
Capitalization
2.01B
9 days until earnings call
STRO
Price
$0.84
Change
+$0.04 (+5.00%)
Updated
Jul 22, 10:55 AM (EDT)
Capitalization
67.57M
16 days until earnings call
Interact to see
Advertisement

DNLI vs STRO

Header iconDNLI vs STRO Comparison
Open Charts DNLI vs STROBanner chart's image
Denali Therapeutics
Price$13.83
Change-$0.17 (-1.21%)
Volume$1.16M
Capitalization2.01B
Sutro Biopharma
Price$0.84
Change+$0.04 (+5.00%)
Volume$1.26K
Capitalization67.57M
DNLI vs STRO Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. STRO commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and STRO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (DNLI: $13.83 vs. STRO: $0.80)
Brand notoriety: DNLI and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 77% vs. STRO: 139%
Market capitalization -- DNLI: $2.01B vs. STRO: $67.57M
DNLI [@Biotechnology] is valued at $2.01B. STRO’s [@Biotechnology] market capitalization is $67.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, STRO is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while STRO’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • STRO’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, STRO is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -5.85% price change this week, while STRO (@Biotechnology) price change was +4.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.08%. For the same industry, the average monthly price growth was +18.20%, and the average quarterly price growth was +33.26%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

STRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.01B) has a higher market cap than STRO($67.6M). DNLI YTD gains are higher at: -32.139 vs. STRO (-56.522). STRO has higher annual earnings (EBITDA): -203.18M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. STRO (249M). STRO has less debt than DNLI: STRO (21.4M) vs DNLI (48.6M). STRO has higher revenues than DNLI: STRO (66.4M) vs DNLI (0).
DNLISTRODNLI / STRO
Capitalization2.01B67.6M2,972%
EBITDA-505.16M-203.18M249%
Gain YTD-32.139-56.52257%
P/E RatioN/AN/A-
Revenue066.4M-
Total Cash818M249M329%
Total Debt48.6M21.4M227%
FUNDAMENTALS RATINGS
DNLI vs STRO: Fundamental Ratings
DNLI
STRO
OUTLOOK RATING
1..100
42
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
9190
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (25) in the Pharmaceuticals Major industry is significantly better than the same rating for DNLI (93) in the Biotechnology industry. This means that STRO’s stock grew significantly faster than DNLI’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as DNLI (100) in the Biotechnology industry. This means that STRO’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that DNLI’s stock grew similarly to STRO’s over the last 12 months.

STRO's Price Growth Rating (90) in the Pharmaceuticals Major industry is in the same range as DNLI (91) in the Biotechnology industry. This means that STRO’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that DNLI’s stock grew similarly to STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLISTRO
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARRKF0.780.03
+4.31%
ARRAS MINERALS CORP.
CWSRF13.16N/A
N/A
Chartwell Retirement Residences
SMOPF1.85N/A
N/A
SMARTOPTICS GROUP AS
DWHHF24.28N/A
N/A
Deutsche Wohnen SE
DMXCF0.61-0.01
-1.78%
District Metals Corp.

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.21%
BEAM - DNLI
63%
Loosely correlated
+1.35%
NRIX - DNLI
61%
Loosely correlated
+0.36%
IDYA - DNLI
60%
Loosely correlated
+1.02%
ARWR - DNLI
58%
Loosely correlated
-12.23%
RGNX - DNLI
58%
Loosely correlated
+4.04%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with DNLI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+5.26%
DNLI - STRO
40%
Loosely correlated
-1.21%
BEAM - STRO
40%
Loosely correlated
+1.35%
TCRX - STRO
40%
Loosely correlated
+0.55%
GLSI - STRO
39%
Loosely correlated
+1.47%
PDSB - STRO
39%
Loosely correlated
N/A
More